These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 14580776)

  • 61. Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.
    Oliveira GA; Costa ES; Freitas MS; Dutra FF; Maia SF; Guerra MC; Tabernero MD; Borojevic R; Otazu IB; Silva JL
    Braz J Med Biol Res; 2010 Jun; 43(6):580-4. PubMed ID: 20396859
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D
    Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
    McNamara C; Grigg A; Szer J; Roberts A; Campbell L; Hoyt R; Lynch K; Juneja S
    Clin Lab Haematol; 2003 Apr; 25(2):119-25. PubMed ID: 12641616
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
    Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
    Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
    [No Abstract]   [Full Text] [Related]  

  • 65. An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
    Rowe LR; Brothman AR; Nibley WE; Gaffney MR; Chen Z
    Cancer Genet Cytogenet; 2007 Apr; 174(1):54-6. PubMed ID: 17350467
    [TBL] [Abstract][Full Text] [Related]  

  • 66. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
    Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
    von Bubnoff N; Peschel C; Duyster J
    Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
    Schafhausen P; Dierlamm J; Bokemeyer C; Bruemmendorf TH; Bacher U; Zander AR; Schnittger S; Hochhaus A
    Cancer Genet Cytogenet; 2009 Feb; 189(1):63-7. PubMed ID: 19167615
    [No Abstract]   [Full Text] [Related]  

  • 69. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
    Aleem A; Siddiqui N
    Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chronic myelogenous leukemia.
    Mauro MJ; Druker BJ
    Curr Opin Oncol; 2001 Jan; 13(1):3-7. PubMed ID: 11148678
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; Cortes J; O'Brien S; Faderl S; Thomas D; Giles F; Rios MB; Shan J; Arlinghaus R
    Clin Cancer Res; 2003 Jan; 9(1):160-6. PubMed ID: 12538464
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia.
    Syed NN; Usman M; Adil S; Khurshid M
    Hematol Oncol Stem Cell Ther; 2008; 1(3):166-70. PubMed ID: 20063547
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
    Zonder JA; Pemberton P; Brandt H; Mohamed AN; Schiffer CA
    Clin Cancer Res; 2003 Jun; 9(6):2092-7. PubMed ID: 12796373
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 76. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
    Andersen MK; Pedersen-Bjergaard J; Kjeldsen L; Dufva IH; Brøndum-Nielsen K
    Leukemia; 2002 Jul; 16(7):1390-3. PubMed ID: 12094265
    [No Abstract]   [Full Text] [Related]  

  • 77. Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI).
    Gozzetti A; Tozzuoli D; Crupi R; Gentili S; Bocchia M; Raspadori D; Lauria F
    Eur J Haematol; 2003 Oct; 71(4):313-4. PubMed ID: 12950245
    [No Abstract]   [Full Text] [Related]  

  • 78. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
    Takahashi W; Arai Y; Tadokoro J; Takeuchi K; Yamagata T; Mitani K
    Rinsho Ketsueki; 2006 Feb; 47(2):111-4. PubMed ID: 16529013
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Imatinib: a review of its use in chronic myeloid leukaemia.
    Moen MD; McKeage K; Plosker GL; Siddiqui MA
    Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.